Heidi, Tortus and other clinical AI rivals should respond by making their strongest customer proposition harder to replace, not by automatically copying Tandem's roadmap. More capital changes what a competitor can attempt. It does not establish which additional product your own customers need, or whether they would pay for it.
Strategic analysis, 14 September 2026. The competitive responses discussed here are editorial proposals, not reported decisions by the companies concerned. Product descriptions refer to public material checked on this date.
What Tandem's announcement changes
Tandem announced a $100 million Series B on 14 September 2026, led by the Scaleup Europe Fund, managed by EQT. Its announcement sets out an expansion towards clinic operations, including patient flow, triage, scheduling and communications.
That is a broader ambition than improving a consultation note. It potentially places the company in discussions with operational managers as well as clinicians. However, an announced destination should not be mistaken for a complete product already deployed in every market.
Nor is the starting point simply transcription. Tandem's current clinical decision-support page describes source-linked questions within the consultation workflow. A competitor assessing the threat needs to distinguish capabilities already offered from those still on the roadmap.
The immediate strategic change is therefore increased capacity to pursue adjacent problems. The eventual competitive change will depend on what ships, who adopts it and whether it makes work easier after implementation and review are counted.
Start with the customer you could lose
Imagine a fictional clinical AI company serving general practices. Its customers praise its telephone-consultation workflow but repeatedly ask for more reliable filing into their clinical system. Following a rival's funding announcement, the company could announce scheduling, research, inbox management and a new mobile assistant. It could also fix the filing problem.
The second response sounds less ambitious. It might nevertheless protect more customer value, particularly where failed filing causes staff to repeat work or check whether a note reached the right record. This is an illustrative choice, not a description of any named supplier's performance.
Before changing direction, management should ask three questions in plain language. Which customers are genuinely considering switching? What task do they expect the alternative to complete? What evidence would persuade them to stay? Answers such as "the competitor is better funded" do not yet identify a product requirement.
A fourth question prevents defensive overbuilding: is the threatened task one the company needs to own? Customers might happily use a separate evidence tool, but find a separate filing step unacceptable. Both are adjacent to documentation; only one may be central to their decision to renew.
Four credible responses
Expand the product when the next task genuinely belongs with the existing one. An additional function can make sense when it uses information already available, serves the same buyer and removes a troublesome handover. The team should still define its review process and failure handling. Being able to generate a proposed action is not the same as completing the surrounding work reliably.
Expansion becomes harder to justify when the new function has a different buyer, procurement process or operational owner. A clinician's enthusiasm for a personal tool does not automatically provide permission to change a practice's appointment system. Product adjacency is not necessarily commercial adjacency.
Deepen a workflow when customers already depend on it. This means making the entire task dependable, including less visible steps such as recovery after interruption, correction, saving and confirmation. The objective is not a more impressive demonstration. It is fewer unfinished or repeated tasks in ordinary use.
Depth also creates a clearer evaluation. A company can ask whether a specific type of consultation reaches an approved, filed record with less total effort. That is more informative than asking users whether the product feels innovative.
Partner when another organisation can remove a bottleneck better. Existing software relationships may help with access, integration or support. The important question is not how many customers the partner can theoretically reach, but whether the relationship makes adoption and everyday use easier. Responsibility for failures must remain intelligible to the customer.
Concentrate on a different professional need when overlap is limited. A product can serve the same clinician without competing for the same purchase. A learner preparing for a clinical examination needs practice, feedback and revision continuity. A service procuring documentation software needs a functioning operational workflow. Treating those as one market obscures both propositions.
Heidi, Tortus and Abridge do not start from the same position
As checked on 14 September 2026, Heidi presents scribing, dictation and evidence products. The strategic question is whether users obtain enough value from the available combination to keep choosing it. Adding another function is only one possible answer.
Tortus emphasises NHS deployment and its relationship with existing clinical workflows. Its opportunity could lie in making a particular service easier to run, rather than matching every country's launch timetable.
Abridge presents an enterprise offering spanning clinician documentation, revenue-cycle work, nursing and clinical decision support. For that starting position, implementation within existing accounts may matter as much as a new geographical announcement.
These descriptions identify different strategic options. They do not establish which supplier currently has better retention, lower support costs or superior clinical performance. Those would require comparable data that the product pages do not provide.
Replace the funding league table with a customer-value scorecard
The following is a proposed evaluation framework, not a set of measured company results. It asks whether a competitive response changes the customer's experience rather than merely changing the product brochure.
| Question | Useful evidence | Misleading substitute |
|---|---|---|
| Do people continue using it? | Repeat use among users with a relevant opportunity to use the tool | All accounts ever created |
| Does work reach completion? | Reviewed outputs successfully reaching their intended destination | Drafts generated |
| Is deployment getting easier? | Implementation work and unresolved support needs by setting | Integration logos alone |
| Do organisations renew for a clear reason? | Renewal decisions linked to defined service requirements | A new procurement announcement |
| Are benefits supported? | Transparent local evaluations and appropriately designed independent studies | Funding or marketing claims |
Denominators matter. A clinician on leave has no opportunity to use a consultation tool. A doctor whose role changes may stop needing an examination subscription. Neither event should automatically be interpreted as a product failure. Conversely, an account retained because it is bundled into a contract does not demonstrate enthusiastic individual adoption.
Evaluation should also include people who stop using the product. Otherwise, the feedback exercise risks describing only those for whom the implementation already worked. Asking why a task was abandoned can be more useful than collecting another satisfaction score from a frequent user.
Knowledge and learning remain a distinct proposition
This analysis is published by iatroX and includes iatroX among the platforms discussed. Its September 2026 offering combines referenced clinical information with questions, Socratic tutoring and study tools. That makes it a useful example of concentrating on a professional need rather than trying to operate a clinic.
The distinction is not that workflow platforms cannot support learning, or that specialists are protected from competition. It is that a note, an evidence answer and a successful practice session are different deliverables. Each needs its own assessment of usefulness.
A clinician may reasonably use an organisation's documentation system and a separate learning environment. The relevant comparison is whether each does its job well enough to justify the attention, cost and review it requires. There is no need to manufacture a contest in which only one application can remain.
Which response fits which situation?
For a supplier losing customers because a core task remains awkward, workflow improvement should come before another distant feature. For one facing a genuine distribution barrier, a partnership may be more useful than a broad rebuild. For an enterprise vendor with strong demand from existing accounts, deeper implementation may beat immediate expansion into another country.
For a specialist whose users have a well-defined learning or reference need, the priority is to demonstrate that particular value while remaining open to complementary tools. Focus is a choice to test, not an exemption from competition.
The strongest response to Tandem's funding may therefore be to become more valuable to a particular customer, rather than more similar to Tandem. The rest of this series examines that choice through Heidi's adoption, evidence-search behaviour, NHS workflow depth and the economics of bundled learning tools.
Frequently asked questions
Does Tandem's funding mean competitors must offer a clinic operating system?
No. A broader product is justified when it solves a sufficiently important customer problem and can be implemented responsibly, not simply because another company announced one.
Are all clinical AI suppliers direct competitors?
No. Their functions overlap, but documentation, evidence retrieval, clinic operations and professional learning can involve different users, buyers and intended outputs.
What would show that a competitive response is working?
Look for sustained relevant use, completed workflows, manageable implementation effort and customers renewing for a clear reason. Clinical or educational benefit requires evidence appropriate to the particular claim.